{
    "N/R/U": null,
    "Applicant": "Fresenius Kabi USA, LLC",
    "BLA Number": "761449",
    "Proprietary Name": "Tyenne",
    "Proper Name": "tocilizumab-aazg",
    "BLA Type": "351(k) Biosimilar",
    "Strength": "162MG/0.9ML",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "March 14, 2025",
    "Ref. Product Proper Name": "tocilizumab",
    "Ref. Product Proprietary Name": "Actemra",
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2146",
    "Product Number": "002",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}